NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE) Valuation After Accelerated SKYWAY Trial Timeline And Rising Investor Interest
Spyre Therapeutics (SYRE) is back in focus after completing recruitment for the rheumatoid arthritis arm of its SKYWAY Phase 2 trial, which has pulled forward the expected topline readout to the third quarter of 2026.
See our latest analysis for Spyre Therapeutics.
At a share price of $43.06, Spyre’s momentum has been strong, with a 30 day share price return of 17.55% and a 90 day gain of 28.65%. The 1 year total shareholder return of 134.02% and 3 year total shareholder return above 4x...